Form 4: Revolution Medicines Executive Sells Shares to Cover Tax Obligations

Stephen Michael Kelsey, President of Research and Development at Revolution Medicines, sold 3,294 shares of common stock on March 17, 2025, to cover tax obligations related to vesting restricted stock units.

Summary

• Stephen Michael Kelsey, President of Research and Development at Revolution Medicines, sold 3,294 shares of common stock on March 17, 2025.
• The sale was executed at a price of $39.0403 per share.
• The transaction was made pursuant to a Rule 10b5-1 trading plan adopted on May 31, 2023.
• The purpose of the sale was to satisfy the reporting person's tax withholding obligation upon the vesting of restricted stock units (RSUs) after July 15, 2023.
• Following the transaction, Kelsey directly owns 293,051 shares of Revolution Medicines common stock, including 104,850 RSUs.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing related to an insider stock sale for tax purposes. It doesn't contain any information that would significantly impact investor sentiment positively or negatively.

Industry Context

Sales by company insiders are a common occurrence, often related to tax obligations or diversification strategies. The use of a pre-arranged Rule 10b5-1 trading plan suggests the sale was planned and not based on any inside information.

Stakeholder Impact

• The sale of shares by an executive could have a minor impact on shareholder sentiment, but is unlikely to be significant given the context of tax obligations and the use of a pre-arranged trading plan.

Key Dates

Keywords

Revolution Medicines, RVMD, Stephen Michael Kelsey, Form 4, Insider Trading, Rule 10b5-1, Stock Sale, Tax Obligations, RSUs, Executive Compensation